CLEARPOINT NEURO INC

ClearPoint Neuro’s RMAT‑approved cell‑replacement therapy for Parkinson’s shows how its navigation & cannula tech can accelerate regenerative medicine breakthroughs.

ClearPoint Neuro’s Q4 2025 earnings reveal R&D‑heavy biotech growth; learn why investors value its $435 M market cap and gene‑therapy innovation.

ClearPoint Neuro Inc. reported a record $9.2 million in revenue for Q2 2025, but fell short of earnings expectations, highlighting the company’s ongoing challenges in managing costs and investing in research and development.

ClearPoint Neuro Inc. has reported a 70% growth in revenue for Q1 2025, securing a $110 million investment from Oberland Capital and positioning itself for further growth in the health care sector.